For our next community meeting we will be getting an update on the status of long-acting injectable HIV therapy as well as on the local rollout of a revamped ACTG study of one such injectable therapy.

Our meeting will be held on Tuesday, February 25 at 5:30 PM on the 2nd Floor of the West Clinic at Harborview Medical Center, down the hall from Madison Clinic.

We’ll provide dinner for you. We can cover parking in the Harborview View Park Garage. Bus tickets are also available.

And you can easily RSVP for this meeting just by indicating that you are “going” on this event page.

If physically traveling to us is a challenge, you can always choose to join us via our Zoom meeting link
https://uw-phi.zoom.us/j/474976647
Meeting ID: 474 976 647
Dial for audio by phone
+1 669 900 6833 US (San Jose)
+1 646 558 8656 US (New York)
Meeting ID: 474 976 647

MORE INFO ABOUT THE MEETING

You may remember that FDA review of the injectable cabotegravir/rilpivirine strategy as an HIV treatment would take place before the end of 2019.

Most people (including me) expected FDA approval.

Based on the results of the phase 3 efficacy studies called ATLAS and FLAIR, we know that injectable CAB/RPV is safe, well-tolerated, and very popular (among those who chose to participate in the studies).

Participant-reported outcomes consistently showed they vastly preferred the long-acting therapy to the pill or pills they took previously.

The treatment even already has a brand name — Cabenuva.

So, given all this, why did the FDA refuse to approve the first long-acting injectable HIV therapy?

We will also discuss the upcoming revamped Injectables Plus Study that we are hoping to open locally.

This small study is trying to find out if a combination of an investigational long-acting HIV drug (cabotegravir-LA) and a monoclonal antibody (VRC07-523LS) would be safe and effective at maintaining an undetectable viral load when given as injectable long-acting agents in people living with HIV.

This study will function like the antiretroviral switch studies you may be familiar with, but participants will be switching from their current regimen to a novel combination of injectable long acting ART plus a monoclonal antibody (mAb) which has been shown to be 8 times more potent and could neutralize 96% of HIV strains.

Our study will be a way for people interested in this new long-acting treatment paradigm to support the development of more options for people living with HIV.

We hope you will join us for this update on injectable HIV therapy on Feb 25th.